Jodie Morrison

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Prior to Cadent, Ms. Morrison served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc. (managing the process leading to the merger with Akebia Therapeutics) and Acting Chief Operating Officer at Syntimmune (acquired by Alexion). Previously, she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. (where she took that company public in 2014) and prior to being appointed President and CEO, she held other senior positions including Chief Operating Officer and VP/Head of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc.

Ms. Morrison currently serves as Chair of the Ribon Therapeutics board and sits on the Board of Aileron Therapeutics (ALRN). She previously served on the pre/post-merger boards for Keryx/Akebia Biopharmaceuticals and Tokai/Novus Pharmaceuticals.

Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.